TrialSpark licenses sprifermin, an investigational first-in-class disease modifying treatment for osteoarthritis, from Merck KGaA, Darmstadt, Germany and announces formation of High Line Bio

/PRNewswire/ -- TrialSpark announced today the formation of High Line Bio following the acquisition of worldwide rights to sprifermin from Merck KGaA,...

Related Keywords

Germany ,United States ,Canada ,John Doerr ,Michael Moritz ,Sam Altman ,Gavin Corcoran ,Merck Kga ,Merck Kgaa ,Serono ,Sequoia Capital ,Chief Medical Officer ,Line Bio ,High Line Bio ,Lachy Groom ,Casdin Capital ,Thrive Capital ,Spark Capital ,Felicis Ventures ,Sound Ventures ,Trialspark ,